These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208 [TBL] [Abstract][Full Text] [Related]
10. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220 [TBL] [Abstract][Full Text] [Related]
11. Infliximab for ulcerative colitis in children and adolescents. McGinnis JK; Murray KF J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529 [TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Lees CW; Heys D; Ho GT; Noble CL; Shand AG; Mowat C; Boulton-Jones R; Williams A; Church N; Satsangi J; Arnott ID; Aliment Pharmacol Ther; 2007 Aug; 26(3):411-9. PubMed ID: 17635376 [TBL] [Abstract][Full Text] [Related]
13. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Russo EA; Harris AW; Campbell S; Lindsay J; Hart A; Arebi N; Milestone A; Tsai HH; Walters J; Carpani M; Westaby D; Thillainayagam A; Bansi D; Ghosh S Aliment Pharmacol Ther; 2009 Feb; 29(3):308-14. PubMed ID: 19035973 [TBL] [Abstract][Full Text] [Related]
14. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Sandborn WJ; Rutgeerts P; Feagan BG; Reinisch W; Olson A; Johanns J; Lu J; Horgan K; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF Gastroenterology; 2009 Oct; 137(4):1250-60; quiz 1520. PubMed ID: 19596014 [TBL] [Abstract][Full Text] [Related]
15. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777 [TBL] [Abstract][Full Text] [Related]
16. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. Dean KE; Hikaka J; Huakau JT; Walmsley RS J Gastroenterol Hepatol; 2012 Mar; 27(3):487-92. PubMed ID: 22098019 [TBL] [Abstract][Full Text] [Related]
17. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Jakobovits SL; Jewell DP; Travis SP Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506 [TBL] [Abstract][Full Text] [Related]
18. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related]
19. A review of infliximab use in ulcerative colitis. Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261 [TBL] [Abstract][Full Text] [Related]
20. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]